Friday, July 1, 2011
Medicare Will Continue to Cover 2 Expensive Cancer Drugs - New York Times
Globe and MailMedicare Will Continue to Cover 2 Expensive Cancer DrugsNew York TimesMedicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer. ...If FDA withdraws approval of Avastin for breast cancer, insurers could stop ...Philadelphia InquirerMedicare to Keep Paying for AvastinMedPage TodayFDA panel against use of Avastin for
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment